



CVS Caremark Corporation

Supplemental Financial Information
Preliminary And Unaudited

First Quarter 2013
May 1, 2013

The information in this report includes non-GAAP financial measures related to our company's performance, namely EBITDA and "Adjusted EPS". In accordance with SEC regulations, the definitions of the non-GAAP items mentioned, as well as the reconciliations to comparable GAAP measures, are available on the investor relations portion of our website at info.cvscaremark.com/investors.

Supplemental Information: Statement of Operations

First Quarter 2013

	First Quarter		
	Three months ended		
(In millions, except per share amounts)	March 31, 2013	March 31, 2012	Change
Net revenues	\$ 30,763.2	\$ 30,797.5	(0.1%)
Cost of revenues	25,181.1	25,684.4	(2.0%)
Gross profit	5,582.1	5,113.1	9.2%
gross margin	18.1%	16.6%	154 bps
Operating expenses	3,882.9	3,709.3	4.7%
as a % of net revenues	12.6%	12.0%	(58 bps)
Operating profit	1,699.2	1,403.8	21.0%
operating margin	5.5%	4.6%	97 bps
Interest expense, net	125.8	132.0	(4.7%)
Income from continuing ops before before income tax	1,573.4	1,271.8	23.7%
Amortization	121.7	117.8	3.3%
Adjusted income from cont ops before income tax	1,695.1	1,389.6	22.0%
Adjusted income tax provision	664.5	541.9	22.6%
Adj income from cont ops	1,030.6	847.7	21.6%
as a % of net revenues	3.4%	2.8%	60 bps
Net loss attributable to noncontrolling interest	-	0.9	N/A
Adj income from cont ops attributable to CVS Caremark	1,030.6	848.6	21.5%
as a % of net revenues	3.4%	2.8%	59 bps
Weighted avg diluted common shares outstanding	1,240.6	1,308.8	(5.2%)
Adj EPS from cont ops attributable to CVS Caremark	\$ 0.83	\$ 0.65	28.1%
Depreciation	380.3	305.4	24.5%
Depreciation and amortization	502.0	423.2	18.6%
EBITDA	2,201.2	1,827.0	20.5%
as a % of net revenues	7.2%	5.9%	122 bps

	First Quarter		
	<i>Three months ended</i>		
<i>(In millions, except per claim amounts)</i>	March 31, 2013	March 31, 2012	Change
Net revenues	\$ 18,310.8	\$ 18,299.8	0.1%
Cost of revenues	17,543.2	17,684.0	(0.8%)
Gross profit	767.6	615.8	24.6%
<i>gross margin</i>	4.2%	3.4%	83 bps
Operating expenses	269.1	267.1	0.8%
<i>as a % of net revenues</i>	1.5%	1.5%	(1 bps)
Operating profit	498.5	348.8	42.9%
<i>operating margin</i>	2.7%	1.9%	82 bps
Depreciation and amortization	136.5	121.7	12.2%
EBITDA	635.0	470.5	35.0%
<i>as a % of net revenues</i>	3.5%	2.6%	90 bps
Net revenues:			
Mail choice	5,869.4	5,665.5	3.6%
Pharmacy network	12,391.5	12,584.7	(1.5%)
Other	49.9	49.6	0.6%
Pharmacy claims processed:			
Total	227.6	218.9	4.0%
Mail choice	20.5	20.4	0.6%
Pharmacy network	207.1	198.5	4.3%
Total Adjusted claims	266.0	257.0	3.5%
Generic dispensing rate:			
Total	80.5%	76.5%	400 bps
Mail choice	75.4%	69.0%	640 bps
Pharmacy network	81.0%	77.3%	370 bps
Mail choice penetration rate	22.1%	22.8%	(70) bps

	First Quarter		
	<i>Three months ended</i>		
<i>(In millions)</i>	March 31, 2013	March 31, 2012	Change
Net revenues	\$ 16,051.2	\$ 16,024	0.2%
Cost of revenues	11,098.8	11,451.1	(3.1%)
Gross profit	4,952.4	4,572.400	8.3%
<i>gross margin</i>	30.9%	28.5%	232 bps
Operating expenses	3,415.2	3,274.6	4.3%
<i>as a % of net revenues</i>	21.3%	20.4%	(84 bps)
Operating profit	1,537.2	1,297.8	18.5%
<i>operating margin</i>	9.6%	8.1%	148 bps
Depreciation and amortization	342.4	281.0	21.9%
EBITDA	1,879.6	1,578.8	19.1%
<i>as a % of net revenues</i>	11.7%	9.9%	186 bps
Net revenues:			
Total	0.2%	9.9%	(973 bps)
Pharmacy	(1.1%)	11.1%	(1219 bps)
Front store	3.1%	7.1%	(400 bps)
Same-store increase (decrease):			
Total Sales	(1.2%)	8.4%	(960 bps)
Pharmacy Sales	(2.3%)	9.8%	(1210 bps)
Front store Sales	1.4%	5.3%	(390 bps)
Total prescription volume	2.0%	7.2%	(520 bps)
Total adj. prescription volume*	4.7%	9.2%	(450 bps)
Generic dispensing rate	81.2%	78.1%	310 bps
Rx % of net revenues	69.0%	69.9%	(90 bps)
3rd party % of Rx revenues	96.8%	97.7%	(90 bps)
Retail prescriptions filled	184.7	179.5	2.9%
Adj. retail prescriptions filled*	221.5	210.0	5.5%

* 90-day prescriptions adjusted to 30-day equivalent

First Quarter*Three months ended*

<i>(In millions)</i>	March 31, 2013	March 31, 2012	Change
Net revenues	\$ -	\$ -	N/A
Cost of revenues	-	-	N/A
Gross profit	-	-	N/A
<i>gross margin</i>	<i>N/A</i>	<i>N/A</i>	<i>N/A</i>
Operating expenses	198.5	167.6	18.4%
<i>as a % of consolidated net revenues</i>	<i>0.6%</i>	<i>0.5%</i>	<i>(10 bps)</i>
Operating profit	(198.5)	(167.6)	(18.4%)
<i>operating margin</i>	<i>N/A</i>	<i>N/A</i>	<i>N/A</i>
Depreciation and amortization	23.1	20.5	12.7%
EBITDA	(175.4)	(147.1)	(19.2%)
<i>as a % of net revenues</i>	<i>N/A</i>	<i>N/A</i>	<i>N/A</i>

Supplemental Information: Eliminations

First Quarter 2013

	<i>First Quarter</i>		
	<i>Three months ended</i>		
<i>(In millions)</i>	March 31, 2013	March 31, 2012	Change
Net revenues	\$ (3,598.8)	\$ (3,525.8)	(2.1%)
Cost of revenues	(3,460.9)	(3,450.7)	(0.3%)
Gross profit	(137.9)	(75.1)	(83.6%)
<i>gross margin</i>	3.8%	2.1%	170 bps
Operating expenses	-	-	N/A
<i>as a % of net revenues</i>	N/A	N/A	N/A
Operating profit	(137.9)	(75.1)	(83.6%)
<i>operating margin</i>	3.8%	2.1%	170 bps
Depreciation and amortization	-	-	N/A
EBITDA	(137.9)	(75.1)	(83.6%)
<i>as a % of net revenues</i>	3.8%	2.1%	170 bps